Hepatitis C Virus (HCV) Treatment Completion or Withdrawal

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00674492
First received: May 6, 2008
Last updated: February 20, 2015
Last verified: February 2015
  Purpose

Qualitative pilot study of patients' views of their experience with antiviral treatment for hepatitis C.


Condition
Hepatitis C

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Patients' View of Hepatitis C Treatment Completion or Withdrawal

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Attributes of Treatment Experience [ Time Frame: Zero to five years since ending treatment. ] [ Designated as safety issue: No ]
    Four basic reasons for persisting in antiviral treatment were identified: cure the disease, concern about diminishing time to act (avoid bad end), demonstation of personal strength, and redemption for past behavior.


Enrollment: 21
Study Start Date: May 2008
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
Hepatitis C patients
patients who initiated antiviral treatment for hepatitis C

Detailed Description:

Qualitative pilot study of patient' views of their experiences with antiviral treatment for hepatitis C. Two groups of patients will be sampled: nine who completed a 24 or 48 week course of treatment and nine who withdrew from treatment prior to planned end. Interview data will be analyzed using narrative and grounded theory methods to identify attributes of treatment experience that may discriminate between completion and withdrawal.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

VHA patients who ever initiated antiviral treatment for hepatitis C.

Criteria

Inclusion Criteria:

Ever initiated anitiviral treatment for hepatitis C.

Exclusion Criteria:

none

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00674492

Locations
United States, Massachusetts
VA New England Health Care System
Bedford, Massachusetts, United States, 01730
Sponsors and Collaborators
Investigators
Principal Investigator: Jack A Clark, PhD VA New England Health Care System
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00674492     History of Changes
Other Study ID Numbers: SHP 08-193
Study First Received: May 6, 2008
Results First Received: February 5, 2015
Last Updated: February 20, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Hepatitis C
Digestive System Diseases
Flaviviridae Infections
Hepatitis
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on March 26, 2015